Literature DB >> 15662525

Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways.

Wei-Zhong Wu1, Hui-Chuan Sun, Yue-Fang Shen, Jie Chen, Lu Wang, Zhao-You Tang, George Iliakis, Kang-Da Liu.   

Abstract

An earlier report demonstrated that interferon alpha (IFN-alpha) inhibited tumor growth and recurrence in an MHCC97 xenograft model in nude mice by suppressing tumor angiogenesis rather than by inhibiting tumor cell proliferation. However, the underlying molecular mechanism was not fully elucidated. In this study, we demonstrated that IFN-alpha 2a could down-regulate VEGF expression both in mRNA and in protein levels, as well as down-regulating HIF-1 alpha mRNA expression in MHCC97 cells in vitro. A cDNA micro array analysis followed by Northern and Western blot analysis revealed that PI3 kinase and MAP kinase signaling pathways might be inhibited by IFN-alpha 2a. Blocking the function of IFN-alpha receptor with a specific peptide could eliminate the inhibitory effects of IFN-alpha 2a on VEGF expression. In addition, wortmannin and PD098059, respective inhibitors of the PI3 kinase and the MAP kinase signaling pathways, when used independently or in combination, could also down-regulate the VEGF synthesis and secretion in a similar pattern of IFN-alpha 2a. These observations may lead to the conclusion that IFN-alpha 2a could suppress VEGF synthesis and secretion by down-regulating HIF-1 alpha expression, via inhibition of the PI3 kinase and/or the MAP kinase signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15662525     DOI: 10.1007/s00432-004-0615-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  68 in total

1.  Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.

Authors:  J Zhou; Z Y Tang; J Fan; Z Q Wu; X M Li; Y K Liu; F Liu; H C Sun; S L Ye
Journal:  J Cancer Res Clin Oncol       Date:  2000-01       Impact factor: 4.553

2.  Interaction of Shc with adaptor protein adaptins.

Authors:  Y Okabayashi; Y Sugimoto; N F Totty; J Hsuan; Y Kido; K Sakaguchi; I Gout; M D Waterfield; M Kasuga
Journal:  J Biol Chem       Date:  1996-03-01       Impact factor: 5.157

Review 3.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

Authors:  J Holash; S J Wiegand; G D Yancopoulos
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

4.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.

Authors:  L E Benjamin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

5.  Regulation of vascular endothelial growth factor expression by advanced glycation end products.

Authors:  C Treins; S Giorgetti-Peraldi; J Murdaca; E Van Obberghen
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

Review 6.  Angiogenesis research: guidelines for translation to clinical application.

Authors:  J Folkman; T Browder; J Palmblad
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

7.  Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts: involvement of p38 mitogen-activated protein kinase.

Authors:  O Kozawa; H Kawamura; D Hatakeyama; H Matsuno; T Uematsu
Journal:  Cell Signal       Date:  2000-06       Impact factor: 4.315

8.  Interferon-alpha-induced inhibition of B16 melanoma cell proliferation: interference with the bFGF autocrine growth circuit.

Authors:  M Torcia; M Lucibello; G De Chiara; D Labardi; L Nencioni; P Bonini; E Garaci; F Cozzolino
Journal:  Biochem Biophys Res Commun       Date:  1999-09-07       Impact factor: 3.575

9.  Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate.

Authors:  N Ravindranath; D Wion; P Brachet; D Djakiew
Journal:  J Androl       Date:  2001 May-Jun

10.  Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray.

Authors:  Y Li; Y Tang; L Ye; B Liu; K Liu; J Chen; Q Xue
Journal:  J Cancer Res Clin Oncol       Date:  2002-12-04       Impact factor: 4.553

View more
  15 in total

1.  Modulation of gene expression in MHCC97 cells by interferon alpha.

Authors:  Wei-Zhong Wu; Hui-Chuan Sun; Lu Wang; Jie Chen; Kang-Da Liu; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

2.  Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.

Authors:  Zhaoting Li; Yijia Zhu; Chenchen Li; Ryan Trinh; Xueyan Ren; Fumou Sun; Youfu Wang; Pengzhao Shang; Tong Wang; Min Wang; Sherie L Morrison; Juan Zhang
Journal:  Oncoimmunology       Date:  2017-02-17       Impact factor: 8.110

3.  Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report.

Authors:  Haruomi Nishio; Tatsuo Tsukamoto; Takeshi Matsubara; Yoichiro Okada; Ryosuke Takahashi; Motoko Yanagita
Journal:  CEN Case Rep       Date:  2016-06-20

4.  Cell-specific but p53-independent regulation of vascular endothelial growth factor expression by interferons in human glioblastoma cells.

Authors:  Yongxue Yao; Toshihiko Kubota; Kazufumi Sato; Hiroaki Takeuchi; Yuji Handa; Shigeru Matsukawa
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

5.  The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.

Authors:  Seth G Thacker; Celine C Berthier; Deborah Mattinzoli; Maria Pia Rastaldi; Matthias Kretzler; Mariana J Kaplan
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

6.  A 7-year-old with pulmonary hypertension.

Authors:  James Olin; Steven Abman; R Grady; D Ivy; Mark Lovell; David Partrick; Vivek Balasubramaniam
Journal:  BMJ Case Rep       Date:  2011-04-20

7.  [Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells].

Authors:  S A Wedel; A Mickuckyte; E Juengel; J Jones; L Hudak; D Jonas; R A Blaheta
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

8.  Treatment of Basal Cell Carcinoma Located in the Head and Neck Region with Intralesional Interferon alpha-2a : Evaluation of Long-Term Follow-Up Results.

Authors:  Seher Bostanci; Pelin Kocyigit; Ayşegül Alp; Cengizhan Erdem; Erbak Gürgey
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

9.  VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines.

Authors:  Ene T Raig; Natalie B Jones; Kimberly A Varker; Kristen Benniger; Michael R Go; Jennifer L Biber; Gregory B Lesinski; William E Carson
Journal:  J Interferon Cytokine Res       Date:  2008-09       Impact factor: 2.607

10.  Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis.

Authors:  Michael F Denny; Seth Thacker; Hemal Mehta; Emily C Somers; Todd Dodick; Franck J Barrat; W Joseph McCune; Mariana J Kaplan
Journal:  Blood       Date:  2007-07-16       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.